By Josephine Lembong, PhD, Scientist, Jon Carson, PhD, Strategic Marketing Manager, & Jon Rowley, PhD, Founder and Chief Product Officer
The use of human mesenchymal stem/stromal cells (hMSCs) has evolved since its discovery in the early 1960s. Continuous learning about hMSCs has shifted the paradigm of these cells. While originally MSCs were solely used as a tool for basic research, our thesis is that hMSCs have graduated to the category of true “technology.”
In this paper, we explore how the Gartner Hype Cycle™ model of the maturity and adaptation of technologies, illustrates the rise of the MSC, the fall from grace after multiple failed clinical trials, and what we consider, the stabilization of hMSCs as a true biotechnology.